Deep Learning Integration of Chest CT Imaging and Gene Expression Identifies Novel Aspects of COPD

Junxiang Chen[1], Zhonghui, Xu[2], Li Sun[1], Ke Yu[1], Craig P. Hersh[2,3], Adel Boueiz[2,3], John Hokanson[4], Frank C. Sciurba[5], Edwin K. Silverman[2,3], Peter J. Castaldi[2,6*], Kayhan Batmanghelich[1*]

[1] Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA, USA

[2] Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA

[3] Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA

[4] Department of Epidemiology, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO

[5] Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA

[6] Division of General Internal Medicine and Primary Care, Brigham and Women's Hospital, Boston, MA, USA

* equal contribution

Correspondence and requests for reprints should be addressed to Junxiang Chen, Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, 5607 Baum Blvd, Pittsburgh, PA 15206. E-mail: juc91@pitt.edu

Author Contributions: The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors. J.C., P.J.C, and K.B. designed the study. J.C performed the modeling and statistical analysis and wrote the initial manuscript. Z.X. conducted differential expression and usage analyses. L.S, and K.Y conducted image pre-processing and feature extraction. C.P.H, A.B, J. H., F.C.S, E.K.S and P.J.C assisted with analysis of COPDGene data. All authors contributed to the production of the final manuscript with revision for important intellectual content.

Sources of Support: This work was supported by NHLBI K08 HL141601, R01 HL124233, R01 HL126596, R01 HL147326, U01 HL089897, and U01 HL089856. The COPDGene study (NCT00608764) is also supported by the COPD Foundation through contributions made to an Industry Advisory Board that has included AstraZeneca, Bayer Pharmaceuticals, Boehringer-Ingelheim, Genentech, GlaxoSmithKline, Novartis, Pfizer, and Sunovion.

Competing Interests: PJC has received grant support from Bayer and consulting fees from Novartis and GSK. CPH reports grant support from Bayer, Boehringer-Ingelheim and Vertex, and consulting fees from AstraZeneca and Takeda. EKS has received grant support from Bayer and GSK.

Running head: Deep Learning on CT and Gene Expression in COPD

Subject Category: 3.2 Bioinformatics/Biological Computing

Total word count: 3,415

At a Glance Commentary

Scientific Knowledge on the Subject: Chronic obstructive pulmonary disease (COPD) is characterized by lung structural changes and has a prominent systemic inflammatory component, but the links between lung structural changes and patterns of systemic inflammation in COPD have not been fully described.

What This Study Adds to the Field

We identified novel relationships between lung structural changes and systemic inflammation by simultaneously analyzing CT scans and blood RNA-sequencing gene expression using deep learning models. We identified two distinct Image-Expression Axes (IEAs) that characterize different inflammatory processes associated with emphysema and airway predominant COPD.

This article has an online data supplement, which is accessible from this issue's table of content online at www.atsjournals.org.

Abstract

Rationale: Chronic obstructive pulmonary disease (COPD) is characterized by pathologic changes in the airways, lung parenchyma, and persistent inflammation, but the links between lung structural changes and patterns of systemic inflammation have not been fully described.

Objectives: To identify novel relationships between lung structural changes measured by chest computed tomography (CT) and systemic inflammation measured by blood RNA sequencing.

Methods: CT scan images and blood RNA-seq gene expression from 1,223 subjects in the COPDGene study were jointly analyzed using deep learning to identify shared aspects of inflammation and lung structural changes that we refer to as Image-Expression Axes (IEAs). We related IEAs to COPD-related measurements and prospective health outcomes through regression and Cox proportional hazards models and tested them for biological pathway enrichment.

Measurements and Main Results: We identified two distinct IEAs: IEA_{emph} captures an emphysema-predominant process with a strong positive correlation to CT emphysema and a negative correlation to FEV_1 and Body Mass Index (BMI); IEA_{airway} captures an airway-predominant process with a positive correlation to BMI and airway wall thickness and a negative correlation to emphysema. In multivariable models, IEA_{airway} was significantly associated with the risk of mortality (HR 2.24, CI 1.50-3.33). Pathway enrichment analysis identified 29 and 13 pathways significantly associated with IEA_{emph} and IEA_{airway}, respectively (adjusted p<0.001).

Conclusions: Integration of CT scans and gene expression data identified two IEAs that capture distinct inflammatory processes associated with emphysema and airway predominant COPD.

Keywords: machine learning, emphysema, genomics

(Abstract word count: 234)

Introduction

Chronic obstructive pulmonary disease (COPD) is one of the most prevalent chronic

diseases (1), responsible for approximately 3 million deaths annually (2). COPD is

characterized by persistent respiratory symptoms and poorly reversible airflow limitation

(3). It is associated with an abnormal inflammatory response of the lungs to cigarette

smoke or other noxious particles (4), which results in lung structural changes, including

the loss or narrowing of airways (airways disease) and parenchymal destruction

(emphysema) (5). In addition to its characteristic lung structural changes, COPD also

has a prominent systemic inflammatory component (6,7).

Although lung structural changes and systemic inflammation are characteristic aspects

of COPD, the origin of systemic inflammation and its relation to lung structural changes

remain unclear (8). Computed Tomography (CT) scans provide a detailed

characterization of lung structural changes (9), and blood gene expression captures

systemic inflammatory signals (10). Therefore, we are motivated to understand the

relationship between lung structural changes and systemic inflammation by applying

deep learning to analyze CT imaging and RNA-seq data to identify novel relationships

between alterations in lung structure and patterns of systemic inflammation.

Based on the paradigm of COPD as a collection of treatable traits (11), we hypothesize

that COPD heterogeneity can be described by continuous measures corresponding to

distinct disease processes that are present to varying degrees in affected subjects. We

refer to these continuous measures as "disease axes" (12), and we further hypothesize

that integrative analysis of CT images and blood RNA-seq data can identify disease axes that identify patterns of association between lung structural abnormalities and systemic inflammation as quantified by blood RNA-seq. We tested these hypotheses by training a deep learning model on data from 1,223 subjects in the COPDGene study (13) with CT scans and blood gene expression data. Our analysis identified two disease axes that capture patterns of CT features consistent with emphysema and airway-predominant disease processes that are also associated with emphysema core-peel distribution and specific inflammatory pathways.

Methods

A comprehensive description of methods is included in the online supplement, and all analysis code is available in a GitHub repository (https://github.com/batmanlab/IEA).

Subject Enrollment and Data Collection

COPDGene enrolled 10,198 subjects with a minimum 10 pack-years lifetime smoking history at 21 centers across the United States (NCT00608764, www.copdgene.org) (13). Five-year follow-up data are available for 6,717 subjects, and 10-year follow-up visits are currently being completed. Subjects underwent spirometry, questionnaire assessments, standardized inspiratory and expiratory chest CT imaging, and genome-wide SNP genotyping. At the second visit (year 5) PAXgene blood RNA tubes were collected, and RNA-seq was performed. Each center obtained institutional review board approval, and all participants provided written informed consent.

Learning Image-Expression Axes (IEAs)

CT features were extracted from DICOM image files using the following procedure. Each inspiratory chest CT scan was processed into 581 patches with a size of 32^3 mm^3, following the practice in (14). For each patch, 128 features were generated using context-aware self-supervised representation learning (CSRL) (14), producing a matrix of dimension 581 x 128 for each CT scan.

Image-Expression Axes (IEAs) were constructed where CSRL features were the input to a multilayer perceptron (MLP) that produced a low-dimensional representation for each patch. Further supervised dimension reduction was performed to obtain subject-level Image-Expression Axes (IEAs) using a Product of Experts (PoE) model (15). At this stage, we applied statistically independent constraints with the Hilbert-Schmidt independence criterion (HSIC) (16) to ensure that each IEA captured an independent disease process. A final linear layer used IEAs as the input to predict the expression levels of the genes simultaneously. Parameters of the model were jointly optimized via Adam (17). In the training process, we evaluated the impact of feature selection on genes by testing each gene for the association with the top-128 principal components of the CSRL features in the training dataset, and we evaluated various thresholds for gene inclusion determined by the p-value of the F-test for each gene.

We randomly split the data into training and testing sets with sizes of 923 and 300, respectively. Model training was performed in the training set using five-fold cross-

validation, giving us five models. The final IEAs were given by taking the average value of the IEAs from the five models.

Association of IEAs with Clinical Measurements

We computed Pearson correlation coefficients between IEAs and clinical measurements to understand their association. Full description of the measurements are included in the supplement. Multivariable analyses were conducted by training Ordinary Least Squares (OLS) models for continuous measurements and logistic regression models for categorical measurements. We conducted a survival analysis (starting from the second visit in the supplement)with the Cox proportional hazards model(18). A full description of these models, including model covariates, is provided in the online supplement.

Comparison of IEAs to Other Disease Axes

We compared IEAs to the following disease axes: 1. COPD Factor Analysis Axes (FAs): Previously published phenotype disease axes identified through factor analysis(19). 2. PCA Image Only Axes (PCA-Is): Disease axes constructed by applying Principal Component Analysis (PCA) to the CSRL features. The comparative analyses included calculation of Pearson correlation coefficients between IEAs and other disease axes, association analyses to clinical measurements, and comparison of nested models for clinical outcomes utilizing IEAs, FAs, and PCA-Is to determine whether IEAs improved the performance of models already containing FAs and/or PCA-Is.

Differential Expression and Usage Analyses

To identify the genes and pathways associated with IEAs, we performed differential gene expression analysis using limma and voom(20,21). Multiple comparisons were corrected with the *Benjamini-Hochberg* method to control the false discovery rate (FDR) at 10%(22). Gene Ontology (GO) pathway enrichment analysis was performed for pathways in the "Biological Process" category using the TopGO (v2.33.1) method (23). The threshold for statistical significance was an adjusted P-value < 0.001.

Results

One thousand two hundred and twenty-three subjects in the COPDGene study with complete CT scan and blood RNA-seq data were analyzed, and the flow diagram for the selection of subjects for analysis is shown in Supplemental Figure E1. Analyzed subjects were 50% female, 82% non-Hispanic white, and 18% African American, and the average age of the subjects was 67 years. The GOLD spirometric stage distribution of subjects was 42.5% GOLD 0, 44.0% in GOLD 1-4, and 13.5% with preserved ratio impaired spirometry (PRISm). For model training and validation, subjects were split into training and test sets, with no statistically significant differences in demographic or key clinical characteristics between these groups (Table 1).

IEA Model Training and Reproducibility Analysis

A schematic overview of the model training process is shown in Figure 1, and the data flow is summarized in Supplemental Figure E2. To maximize the stability of the IEAs and reduce the effects of sampling variability, we used nested cross-validation in the

model training process to select the number of genes included in the model and the number of IEAs identified. For gene selection, we tested genes in the training data for the association to the top 128 principal components of the CSRL image features using an F-test, and a series of p-value thresholds for gene inclusion were explored, ranging from $p = 1\times10^{-6}$ to $p = 1$. The resulting IEAs were found to be stable across the entire range of p-value thresholds, and the threshold corresponding to p=0.01 was selected (Pearson's r for IEAs across cross-validation folds ≥ 0.96, Supplemental Table E1). With this threshold, 4,685 genes were included in the final model. The number of IEAs identified by the model was determined by the amount of gene expression variance explained, which was the highest with two IEAs (Figure 2).

IEA Association to Clinical and Radiographic Features and Prospective Outcomes

To provide a clinical interpretation of the IEAs, we calculated their correlation to a range of COPD-related clinical and imaging measurements (Table 2). We refer to the first IEA as the emphysema axis (IEA_{emph}), because it demonstrates a pattern of clinical associations consistent with quantitative emphysema. Specifically, higher levels of IEA_{emph} were associated with lower lung function,greater emphysema, and lower BMI. The second IEA is consistent with airway disease and is referred to as IEA_{airway}. Higher levels of IEA_{airway} were associated with higher BMI, thicker airways, and less emphysema. The IEAs were uncorrelated with each other, suggesting that they may capture different underlying disease processes.

As shown in Table 2, both IEAs were negatively associated with emphysema peel/core distribution ($Q_{perc15_{peel-core}}$), indicating that higher IEA values are associated with more emphysema in the core/central regions of the lung. To explore this association further we preformed sensitivity analyses , in which the lung was separated into concentric bands according to the distance to the lung boundary as described in the supplement.

To determine whether the IEAs provided clinical information in addition to standard clinical and imaging measures (including perc15 and airway wall thickness), we tested the significance of adding IEAs to regression models for various COPD-related measures (Table 3, Table 4, and Supplemental Tables E3 and E4). After adjusting for standard demographic variables and quantitative imaging measures, both IEA_emph and IEA_airway were significantly associated with FEV_1 %predicted and SGRQ total score. IEA_emph was also associated with FEV_1/FVC, and IEA_airway was associated with mMRC dyspnea score, 6-minute-walk distance, and overall mortality rate.

COPD Subgroups Defined by IEAs and Comparison to Existing COPD Subtypes

To further understand the clinical characteristics of COPD subgroups defined by IEAs, we divided the IEA space into four quadrants (Figure 3) and computed the average characteristics of each subgroup (Supplemental Tables E5). As expected, subjects with low IEA_emph/low IEA_airway values had the least obstruction (mean FEV1 89.2% predicted), the highest percentage of GOLD spirometric grade 0 subjects, low emphysema, and the thinnest airways. Subjects with high IEA_emph/low IEA_airway values

had characteristics consistent with emphysema-predominant COPD, namely high emphysema and low BMI, with about 70% of GOLD grade 4 subjects present in this group. Subjects with low IEA_{emph}/high IEA_{airway} values had an airway-predominant profile with thick airway walls, elevated BMI, and the greatest proportion of PRISm subjects. Subjects with high IEA_{emph}/high IEA_{airway} had the highest SGRQ total score, highest mMRC dyspnea scores and shortest 6-minute walk distance. In terms of COPD progression, the groups differed significantly in mortality risk ($p<0.001$) and frequent exacerbation status (2 or more exacerbations in one year) but did not change in FEV1. The group with the highest mortality was high IEA_{emph}/high IEA_{airway} followed by high IEA_{emph}/low IEA_{airway}. The latter group also had the highest percentage of subjects with frequent exacerbations, both for retrospective ($p<0.001$, chi-square test of all groups) and prospective exacerbations ($p=0.048$).

To place IEA_{emph} and IEA_{airway} in the context with previously reported subtypes and disease axes in COPDGene, we compared these axes directly with the previously reported k-means subtypes (24) and factor-analysis derived disease axes (FAs) (19). In Figure 4, we observe that the highest values of IEA_{emph} are found in the severe emphysema k-means subtype, and the highest values of IEA_{airway} are found in the airway-predominant k-means subtype, confirming our clinical interpretation of these disease axes. Since the FAs also showed patterns consistent with emphysema (FA_{emph}) and airway-predominant disease (FA_{airway}), we compared the IEAs to the FAs and observed that IEA_{emph} and FA_{emph} showed a reasonably strong correlation (Pearson's r = 0.58), but the IEA_{airway} and FA_{airway} axes showed only modest correlation (Pearson's r

= 0.28, see Supplemental Table E6). Examination of the pattern of clinical associations

for IEA$_{airway}$ and FA$_{airway}$ revealed that while airway axes were positively correlated to

airway wall thickness, IEA$_{airway}$ is negatively correlated to emphysema whereas FA$_{airway}$

is positively correlated, suggesting that IEA$_{airway}$ captures a more "pure" airway

phenotype (Supplemental Table E7). To determine whether the IEAs provided

additional information about COPD phenotypes (FEV1 % of predicted, FEV1/FVC,

SGRQ, mMRC, retrospective frequent exacerbations, and 6-minute walk distance) and

COPD progression (mortality and prospective frequent exacerbations) above and

beyond FAs, we constructed baseline models for each COPD phenotype and

progression measurements with FAs included and then compared them to models

including both FAs and IEAs. In most cases the models with IEAs included

outperformed the baseline models (p<0.001 for all COPD phenotypes and mortality,

Supplemental Tables E8 and E9).

Comparison to PCs based on Images Alone

After observing that IEAs contain additional clinically relevant information relative to

standard features extracted from CT images, we sought to determine whether the

additional information came only from applying dimension reduction to the CT images

(CSRL features), or whether there was added value from our algorithm that combined

the CT features with gene expression. To make this comparison, we constructed

disease axes from images only by using PCA to extract the top-2 PCs of the CSRL

features, denoted as PCA-Is. We then compared the predictive performance of linear

models that utilize both IEAs and PCA-Is with the nested version that involve the PCA-Is

only, and we observed that the models including IEAs were superior to models with PCA-Is only for all of the six studied COPD phenotypes as well as prospective exacerbations and mortality (p<0.001, Supplemental Tables E10 and E11). These results suggest that by incorporating gene expression data during training, IEAs extract more clinically important information than similar methods that utilizing imaging features only.

IEAs are associated with inflammatory pathways

To understand the biological aspect of the IEAs, we first confirmed that IEAs explained a greater proportion of gene expression variance that PCA-Is as demonstrated in Figure 5, which shows that IEAs explain a greater proportion of variation on a per-gene basis than PCA-Is (557 genes with R^2 >10% for IEAs versus 68 genes with R^2 >10% for PCA-Is).

To identify specific biological processes associated with each IEA, we performed differential expression and pathway enrichment analysis. We identified 6,494 and 3,815 genes associated at an FDR of 10% with IEA_{emph} and IEA_{airway}, respectively (Supplemental Tables E12 and E13). Gene Ontology pathway enrichment identified 29 and 13 enriched pathways (p-value < 0.001) for IEA_{emph} and IEA_{airway}, respectively (Supplemental Tables E14 and E15). The most significantly associated pathway for IEA_{emph} was neutrophil degranulation whereas IEA_{airway} had strongest enrichment for RNA processing. The most significant pathway results are shown in Table 5.

Discussion

In this paper, we used deep learning to identify novel connections between lung imaging features and blood gene expression. The deep learning model provided novel disease axes, i.e. IEAs, that captured elements of shared variability between CT scans and blood RNA-seq, and we demonstrated 1) that these IEAs are associated with important COPD-related physiologic and functional measures, 2) that these associations contained information that is independent from pre-existing, standard clinical and imaging variables, 3) that the IEA$_{airway}$ axis is significantly associated with prospective mortality in multivariable models, and 4) that IEAs capture distinct patterns of connection between lung structural abnormalities and systemic inflammation.

Many of our main results are consistent with our current understanding of COPD. IEAs capture the two cardinal pathologies of COPD, emphysema and airways disease; but clearer links between these aspects of lung structure and systemic inflammation emerge from the joint analysis of CT images and blood RNA-seq. First, neutrophilic inflammation was strongly associated to the emphysema but not the airways axis. This agrees with the prominent role of neutrophils in alpha-1 antitrypsin associated (AAT) emphysema(25), and it provides further support for the role of neutrophils in the emphysema of "typical" COPD. There is evidence as well for a role for specific adaptive immune processes that show significant enrichment for both IEA$_{emph}$ and IEA$_{airway}$, though the inflammatory signals that we observed in blood differ from the B-cell predominated signatures that have been observed in some lung transcriptomic studies

of emphysema(26). The biological pathway enrichments we observed are consistent with previous reports of the association of emphysema to biomarkers related to systemic inflammation, oxidative stress, and elevated plasma fibrinogen levels(27). IEA_{airway} is strongly correlated to BMI, which coincides with a previous hypothesis that obesity-related adipose tissue hypoxia and systemic hypoxia due to reduced pulmonary function contribute to the systemic inflammation of COPD(28). Future studies including single cell transcriptomic data could better identify the association of emphysema and airways disease with specific types of innate and adaptive inflammatory cells.

While our IEAs seem most descriptive of emphysema and airways disease, they are not completely correlated to standard CT measurements of emphysema and airways disease, and they differ notably from machine-learning disease axes based on imaging alone (PCA-Is) or based on imaging and spirometry (FAs) (19). While none of these representations of emphysema and airways disease is demonstrably superior to the others, the IEA axes have a clear interpretation due to the integrative nature of the deep learning algorithm whose goal was to find shared variability between CT images and transcriptomic patterns in the blood. The fact that the IEA_{airway} axis had a negative correlation to emphysema, while the FA_{airway} axis was positively correlated to emphysema, suggests that the IEA_{airway} axis may be a "purer" representation of airway disease. The clinical relevance of these axes was demonstrated through regression models showing that IEAs were significantly associated to a wide range of COPD-related measures, including mortality. In the future, these algorithms can be extended to incorporate additional sources of molecular or imaging data.

While the IEAs primarily captured patterns of emphysema and airway-predominant COPD, they were also significantly correlated with core versus the periphery ("peel") emphysema distribution. Previous work has demonstrated numerous clinically relevant associations to aspects of emphysema distribution, most notably for core/peel and apical/basal emphysema distribution(29-33), and a machine learning analysis of images alone also identified peel-core emphysema distribution as an important dimension of COPD-related variability(34). Our analysis suggests that systemic inflammation is most strongly associated to core/peel rather than apical/basal emphysema distribution, and that the amount of emphysema in the core region is associated with more severe disease along both the IEA$_{emph}$ and IEA$_{airway}$ axes. Since quantification of the lung peel can be influenced by technical factors related to lung segmentation, we conducted sensitivity analyses that confirmed a consistent association for the IEA$_{emph}$ axis, whereas the IEA$_{airway}$ association was clearly present only when the analysis included the outermost lung regions. Accordingly, we have high confidence in the IEA$_{emph}$ association to core/peel distribution, but it is not clear whether the IEA$_{airway}$ axis association reflects a true biological relationship or technical artifacts.

By collecting CT scans, blood transcriptomics, and detailed phenotype data on thousands of current and former smokers enriched for COPD, the COPDGene Study provides a novel opportunity for the application of machine learning to better understand the connections between the lung structure in COPD and molecular mechanisms of systemic inflammation. Like all machine learning models, the construction of our model

required many explicit and implicit design choices. In our model, we extracted patch-level representations via self-supervised learning. Such methods are capable of extracting generalized and semantically meaningful features(35). The linear independence assumption in our model was intended to identify IEAs that captured distinct underlying disease processes and increase the reproducibility of our model. Unlike previous studies that explore the relationship between COPD imaging and omics by associating previously discovered image patterns to omics data(24,36,37), our method potentially identifies new image patterns that have not been previously explored.

The main strengths of this study are: 1) The joint analysis of full DICOM data from CT images and gene expression data via deep learning is novel and provides new biological and clinical insight into COPD. 2) The sample size is large, allowing for more power to identify novel discoveries. 3) We used a number of techniques to improve the reproducibility of our disease axes, including cross-validation, sensitivity analysis, and the use of constraints in our modeling procedure. The main limitations are: 1) Our study is limited to blood RNA biomarkers, which capture systemic inflammation but not other important aspects of the COPD inflammatory response such as lung gene expression and protein biomarkers. 2) Our analysis was limited to the COPDGene study . In the future, such analyses could be conducted in other ongoing studies collecting CT scan and omics data in populations enriched for COPD.

In summary, deep learning applied to CT images and transcriptomic biomarkers in COPD identified two main inflammatory processes related to CT image features that can be broadly defined as emphysema and airways disease. The emphysema-related process was most enriched for pathways related to neutrophilic inflammation, and the airways axis differed from previously reported disease axes learned from phenotypic data alone and represented a "purer" representation of airways disease that was negatively correlated with emphysema. Finally, there was also a strong relationship between core-peel distribution of emphysema and systemic inflammation. In the future, these integrative machine learning methods can be refined for more fine-grained interpretability and extended to include other sources of biological information.

References

1.   Adeloye D, Chua S, Lee C, Basquill C, Papana A, Theodoratou E, et al. Global and regional estimates of COPD prevalence: Systematic review and meta–analysis. Journal of Global Health 2015;5.

2.   Abubakar I, Tillmann T, Banerjee A. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study. Lancet 2013;385:117–171.

3.   Global initiative for chronic obstructive lung disease. Global Strategy for Prevention, Diagnosis, and Management of chronic obstructive pulmonary disease. 2021.

4.   Rabe K, Hurd S, Anzueto A, Barnes P, Buist S, Calverley P, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine 2007;176:532-555.

5.   Patel B, Coxson H, Pillai S, Agustí A, Calverley P, Donner C, et al. Airway Wall Thickening and Emphysema Show Independent Familial Aggregation in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine 2008;178:500-505.

6.   Barnes P, Celli B. Systemic manifestations and comorbidities of COPD. European Respiratory Journal 2009;33:1165-1185.

7.   Sevenoaks M, Stockley R. Chronic Obstructive Pulmonary Disease, inflammation and co-morbidity – a common inflammatory phenotype? Respiratory Research 2006;7:1–9.

8.   Agustí A. Systemic Effects of Chronic Obstructive Pulmonary Disease: What We Know and What We Don't Know (but Should). Proceedings of the American Thoracic Society 2007;4:522-525.

9.   Milne S, King G. Role of imaging in COPD phenotyping. Respirology 2014;20:522-523.

10. Bahr T, Hughes G, Armstrong M, Reisdorph R, Coldren C, Edwards M, et al. Peripheral Blood Mononuclear Cell Gene Expression in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory Cell and Molecular Biology 2013;49:316-323.

11. Agusti A, Bel E, Thomas M, Vogelmeier C, Brusselle G, Holgate S, et al. Treatable traits: toward precision medicine of chronic airway diseases. European Respiratory Journal 2016;47:410-419.

12. Kinney GL, Santorico SA, Young KA, Cho MH, Castaldi PJ, San José Estépar R, et al. Identification of chronic obstructive pulmonary disease axes that predict all-cause mortality: the COPDGene study. American journal of epidemiology 2018;187:2109–2116.

13. Regan E, Hokanson J, Murphy J, Make B, Lynch D, Beaty T, et al. Genetic Epidemiology of COPD (COPDGene) Study Design. COPD: Journal of Chronic Obstructive Pulmonary Disease 2011;7:32-43.

14. Sun L, Yu K, Batmanghelich K. Context matters: Graph-based self-supervised representation learning for medical images. InProceedings of the. Paper presented at: AAAI Conference on Artificial Intelligence. AAAI Conference on Artificial Intelligence2021.

15. Hinton G. Training Products of Experts by Minimizing Contrastive Divergence. Neural Computation 2002;14:1771-1800.

16. Gretton A, Bousquet O, Smola A, Schölkopf B. Measuring statistical dependence with Hilbert-Schmidt norms. Paper presented at: International conference on algorithmic learning theory2005; Berlin, Heidelberg.

17. Kingma D, Ba J. Adam: A method for stochastic optimization. 2014. arXiv:1412.6980.

18. Cox D. Regression Models and Life-Tables. Journal of the Royal Statistical Society: Series B (Methodological) 1972;34:187-202.

19.   Young KA, Regan EA, Han MK, Lutz SM, Ragland M, Castaldi PJ, et al. Subtypes of COPD have unique distributions and differential risk of mortality. Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation 2019;6:400.

20.   Ritchie M, Phipson B, Wu D, Hu Y, Law C, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Research 2015;43:e47-e47.

21.   Phipson B, Lee S, Majewski I, Alexander W, Smyth G. Robust hyperparameter estimation protects against hypervariable genes and improves power to detect differential expression. The Annals of Applied Statistics 2016;10:946.

22.   Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society: Series B (Methodological) 1995;57:289-300.

23.   Alexa A, Rahnenführer J. Gene set enrichment analysis with topGO. Bioconductor Improv 2009;27:1-26.

24.   Castaldi PJ, Cho MH, San José Estépar R, McDonald M-LN, Laird N, Beaty TH, et al. Genome-wide association identifies regulatory Loci associated with distinct local histogram emphysema patterns. American journal of respiratory and critical care medicine 2014;190:399–409.

25.   McCarthy C, Reeves EP, McElvaney NG. The role of neutrophils in alpha-1 antitrypsin deficiency. Annals of the American Thoracic Society 2016;13:S297–S304.

26.   Faner R, Cruz T, Casserras T, López-Giraldo A, Noell G, Coca I, et al. Network analysis of lung transcriptomics reveals a distinct B-cell signature in emphysema. American journal of respiratory and critical care medicine 2016;193:1242–1253.

27.   Papaioannou A, Mazioti A, Kiropoulos T, Tsilioni I, Koutsokera A, Tanou K, et al. Systemic and airway inflammation and the presence of emphysema in patients with COPD. Respiratory Medicine 2010;104:275-282.

28.   Tkacova R. Systemic Inflammation in Chronic Obstructive Pulmonary Disease: May

        Adipose Tissue Play a Role? Review of the Literature and Future Perspectives.

        Mediators of Inflammation 2010;2010:1-11.

29.   Mair G, Miller JJ, McAllister D, Maclay J, Connell M, Murchison JT, et al. Computed

        tomographic emphysema distribution: relationship to clinical features in a cohort of

        smokers. European Respiratory Journal 2009;33:536–542.

30.   Gurney JW, Jones KK, Robbins RA, Gossman GL, Nelson KJ, Daughton D, et al.

        Regional distribution of emphysema: correlation of high-resolution CT with pulmonary

        function tests in unselected smokers. Radiology 1992;183:457–463.

31.   Nakano Y, Sakai H, Muro S, Hirai T, Oku Y, Nishimura K, et al. Comparison of low

        attenuation areas on computed tomographic scans between inner and outer segments of

        the lung in patients with chronic obstructive pulmonary disease: incidence and

        contribution to lung function. Thorax 1999;54:384–389.

32.   Haraguchi M, Shimura S, Hida W, Shirato K. Pulmonary function and regional

        distribution of emphysema as determined by high-resolution computed tomography.

        Respiration 1998;65:125–129.

33.   Boueiz A, Chang Y, Cho MH, Washko GR, Estépar RSJ, Bowler RP, et al. Lobar

        emphysema distribution is associated with 5-year radiological disease progression.

        Chest 2018;153:65–76.

34.   Yang J, Angelini E, Balte P, Hoffman E, Austin J, Smith B, et al. Novel Subtypes of

        Pulmonary Emphysema Based on Spatially-Informed Lung Texture Learning: The Multi-

        Ethnic Study of Atherosclerosis (MESA) COPD Study. IEEE Transactions on Medical

        Imaging 2021;40:3652-3662.

35.   Ohri K, Kumar M. Review on self-supervised image recognition using deep neural

        networks. Knowledge-Based Systems 2021;224:107090.

36.   Cho M, Castaldi P, Hersh C, Hobbs B, Barr R, Tal-Singer R, et al. A genome-wide association study of emphysema and airway quantitative imaging phenotypes. American journal of respiratory and critical care medicine 2015;192(5):559-569.

37.   Jeong I, Lim J-H, Oh DK, Kim WJ, Oh Y-M. Gene expression profile of human lung in a relatively early stage of COPD with emphysema. International Journal of Chronic Obstructive Pulmonary Disease 2018;13:2643.

Figure 1. Overview of the machine learning workflow. CT images were processed as 32^3 mm^3 patches from which 128 features were constructed using the Context-Aware Self-supervised Representation learning algorithm (CSRL) (14). These features were the input for a multilayer perceptron (MLP) that processed a 581x128x923 tensor to output a 581x2x923 subject-level data representation. The subject-level latent representation (IEAs) is given by summarizing the patch-level features into a matrix of 2x923. We introduce a linear layer (2 -> 4,685) that estimates gene expression for each subject, taking the IEA as the input. We apply independent constraints to ensure IEAs are independent of each other. The overall objective function is given by minimizing the mean-squared error of the gene expression levels in prediction.

Figure 2. Total variance of the gene expression explained vs. number of IEAs. The figure on the left shows the plot of the 4,685 selected genes. The figure on the right shows the plot for all the genes. The figures show that when the number of IEAs is two, the total variance explained is maximized. We choose the number of IEAs to be two.

Figure 3. Visualization of subjects projected along each identified image-expression axis (IEA) dimension. IEA_{emph} is the emphysema axis, where higher values indicate more severe emphysema. IEA_{airway} is the airway disease axis, where a higher value represents higher BMI and thicker airways. The space defined by these IEAs was used to stratify the cohort into four subgroups based on dividing the IEA space into four quadrants. Lung CT scans and clinical characteristics are shown for one subject in each quadrant, where the red mask represents the emphysema regions ($<$ -950 HU). The characteristics of the four quadrants are summarized in Supplemental Figure E5.

Figure 4. Distribution of IEA$_{emph}$ and IEA$_{airway}$ values grouped by previously published COPD K-means clustering subtypes(24). P-values are obtained using the Kruskal-Wallis test. The symbols "*", "**", and "***" represent p<.05, p<.01, and p<.001, respectively, for a t-test comparing to the Relatively Resistant Smokers Group. No symbol indicates non-significant results.

Figure 5. Histograms for the variances of genes explained (R^2) by the image-expression axes (IEAs) and PCA Image Only Axes (PCA-Is). The figure on the left shows the histogram for the 4,685 selected genes. Within these genes, there are 557 genes with R^2 >10% for IEAs and 68 genes with R^2 >10% for PCA-Is. The figure on the right shows the histogram for all the genes (18,487 genes in total). There are 622 genes with R^2 >10% for IEAs and 69 genes with R^2 >10% for PCA-Is.

	Training (n=923)	Test (n=300)	p-value
Demographics			
Age	66.6 ± 8.4	66.6 ± 9.2	0.961
Gender, %females	49.7%	50.7%	0.778
Race, %African-American	18.6%	19.3%	0.788
Clinical Measurements			
%Current Smoker	30.3%	28.5%	0.661
Body Mass Index (BMI)	29.1 ± 6.4	29.1 ± 5.9	0.646
Pack Years	44.8 ± 24.4	44.3 ± 25.0	0.860
FEV_1 %predicted	77.7 ± 25.1	76.0 ± 24.8	0.226
FEV_1 / FVC	0.67 ± 0.15	0.66 ± 0.15	0.227
SGRQ Total Score	21.3 ± 19.4	22.4 ± 21.1	0.818
mMRC Dyspnea Score	1.1 ± 1.3	1.2 ± 1.4	0.464
6-Minute-Walk Distance	1292 ± 443	1260 ± 433	0.308
Frequent Exacerbator (History)	6.3%	7.7%	0.403
Quantitative CT			
perc15	-922 ± 28	-923 ± 29	0.637
%Emphysema at -950HU	6.9 ± 10.3	7.2 ± 10.8	0.497
%Gas Trapping	21.4 ± 20.2	21.1 ± 19.1	0.612
Pi10	2.2 ± 0.6	2.3 ± 0.6	0.159
%WA segmental	49.9 ± 8.2	50.2 ± 8.2	0.491
$Q_{perc15_{peel-core}}$	-2.5 ± 1.6	-2.5 ± 1.6	0.459
GOLD Stages			
%GOLD 0	43.2%	39.7%	0.300
%GOLD 1	8.5%	10.3%	0.349
%GOLD 2	19.4%	20.5%	0.663
%GOLD 3	11.5%	9.9%	0.471
%GOLD 4	4.6%	5.5%	0.554
%PRISm	12.9%	14.0%	0.611
Longitudinal			
ΔFEV_1 %predicted	-0.3 ± 2.1	-0.3 ± 2.3	0.789
ΔFEV_1 / FVC	-0.0 ± 0.0	-0.0 ± 0.0	0.235
Frequent Exacerbator (Future)	4.8%	8.6%	0.084
5-year Mortality	14.7%	15.2%	0.769

Table 1. Subject characteristics in training and test data. Continuous variables are expressed as means and standard deviations. Categorical variables are expressed as percentages. P-values are obtained using the Kruskal-Wallis test for continuous variables and chi-square test for proportions, comparing the training and test data. FEV_1 = Forced expiratory volume in 1 second; FVC = Forced vital capacity; perc15 = 15th Percentile Hounsfield unit in Inspiratory CT scan; %Gas Trapping: %LAA using

−856 Hounsfield unit threshold on expiratory CT scan; Pi10 = the average wall thickness for a hypothetical airway of 10-mm lumen perimeter on CT; %WA segmental= the percentage of airway wall area for 3rd generation bronchi; GOLD: Global Initiative for Chronic Obstructive Lung Disease; PRISm=Preserved ratio impaired spirometry. $Q_{perc15_{peel-core}} = 100 * log(perc15_{peel} / perc15_{core})$, where the peel region is defined to be <5mm from the lung boundary and the core region is >20mm from the lung boundary. $\Delta FEV_1 \%predicted$ and $\Delta FEV_1/FVC$ are computed by subtracting the visit 3 values from the visit 2 values of FEV_1 *% of predicted* or FEV_1/FVC and dividing them by the number of years between the two visits.

	IEA$_{emph}$	IEA$_{airway}$
Clinical Measurements		
Body Mass Index (BMI)	-0.14*	0.68***
Pack Years	0.28***	0.12*
FEV$_1$%predicted	-0.45***	0.00
FEV$_1$/FVC	-0.65***	0.19***
SGRQ Total Score	0.40***	0.08
mMRC Dyspnea Score	0.40***	0.12*
6-Minute-Walk Distance	-0.22***	-0.30***
Quantitative CT		
perc15	-0.76***	0.54***
%Emphysema at -950HU	0.72***	-0.34***
%Gas Trapping	0.74***	-0.32***
Pi10	0.14*	0.17**
%WA segmental	0.09	0.34***
$Q_{perc15_{peel-core}}$	-0.36***	-0.32***
Longitudinal		
ΔFEV$_1$%predicted	-0.03	0.14
ΔFEV$_1$/FVC	-0.03	0.07
Image-Expression Axes (IEAs)		
IEA$_{emph}$	1.00***	-0.03
IEA$_{airway}$	-0.03	1.00***

Table 2. Pearson's correlation between image-expression axes (IEAs) and COPD-related characteristics and health outcomes. The symbols "*", "**", and "***" represent p<.05, p<.01, and p<.001, respectively. FEV1 = Forced expiratory volume in 1 second; FVC = Forced vital capacity; perc15 = 15th Percentile Hounsfield unit in Inspiratory CT scan; %Gas Trapping: %LAA using −856 Hounsfield unit threshold on expiratory CT scan; Pi10 = the average wall thickness for a hypothetical airway of 10-mm lumen perimeter on CT; %WA segmental= the percentage of airway wall area for 3rd generation bronchi; $Q_{perc15_{peel-core}} = 100\,log(perc15_{peel}\,/\,perc15_{core})$, where the peel region is defined to be <5mm from the lung boundary and the core region is >20mm from the lung boundary; $\Delta FEV_1\,\%predicted$ and $\Delta FEV_1/FVC$ are computed by subtracting the visit 3 values from the visit 2 values of FEV_1 % of predicted or FEV_1/FVC and dividing it by the number of years between the two visits.

	$\beta_{IEA_{emph}}$ (95%CI)	$\beta_{IEA_{airway}}$ (95%CI)
Cross-Sectional		
FEV$_1$ %predicted	0.12** (0.03, 0.21)	-0.33*** (-0.42, -0.25)
FEV$_1$ / FVC	-0.10* (-0.17, -0.02)	-0.06 (-0.13, 0.01)
SGRQ Total Score	0.19** (0.06, 0.31)	0.20*** (0.08, 0.32)
mMRC Dyspnea Score	0.12 (-0.01, 0.24)	0.26*** (0.13, 0.38)
6-Minute-Walk Distance	0.09 (-0.04, 0.21)	-0.40*** (-0.52, -0.28)
Longitudinal		
ΔFEV$_1$ %predicted	-0.07 (-0.31, 0.17)	0.08 (-0.18, 0.34)
ΔFEV$_1$ / FVC	0.03 (-0.22, 0.27)	-0.09 (-0.36, 0.17)

Table 3. Multivariable associations of image-expression axes (IEAs) to continuous COPD-related characteristics and health outcomes. The table reports the β coefficients and corresponding 95% confidence intervals for IEA$_{emph}$ and IEA$_{airway}$ in linear models using the indicated COPD-related measurement or health outcomes as the response variable. All models were adjusted for age, gender, race, pack years, Body Mass Index (BMI), smoking status, perc15, %gas trapping, %airway wall. The symbols "*", "**", and "***" represent p<.05, p<.01 and p<.001, respectively. FEV_1 = Forced expiratory volume in 1 second; FVC = Forced vital capacity. $\Delta FEV_1\ \%predicted$ and $\Delta FEV_1/FVC$ are computed by subtracting the visit 3 value from the visit 2 value of $FEV_1\ \%\ of\ predicted$ or FEV_1/FVC and dividing it by the number of years between the two visits.

Logistic Regression Model	$\beta_{IEA_{emph}}$ (95%CI)	Odds Ratio (95%CI)	$\beta_{IEA_{airway}}$ (95%CI)	Odds Ratio (95%CI)
Frequent Exacerbator (History)	-0.00 (-0.64, 0.64)	1.00 (0.53, 1.89)	0.33 (-0.26, 0.93)	1.40 (0.77, 2.53)
Frequent Exacerbator (Future)	0.26 (-0.99, 1.51)	1.30 (0.37, 4.54)	0.04 (-1.14, 1.23)	1.04 (0.32, 3.42)

Cox Proportional Hazard Model	$\beta_{IEA_{emph}}$ (95%CI)	Hazard Ratio (95%CI)	$\beta_{IEA_{airway}}$ (95%CI)	Hazard Ratio (95%CI)
Mortality	0.01 (-0.45, 0.46)	1.01 (0.64, 1.59)	0.81*** (0.41, 1.20)	2.24*** (1.50, 3.33)

Table 4. Multivariable associations of image-expression axes (IEAs) to frequent exacerbations and mortality. The table reports the β coefficients of the IEA_{emph} and IEA_{airway} and corresponding 95% confidence intervals from logistic regression models for frequent exacerbator status and a Cox proportional hazards model for mortality. All models adjusted for age, gender, race, pack years, Body Mass Index (BMI), smoking status, perc15, %gas trapping, and %airway wall as the covariates. The symbols "*", "**", and "***" represent $p<.05$, $p<.01$, and $p<.001$, respectively. Frequent exacerbator (history) indicated whether the subject had at least two self-reported exacerbations during the 12 months before the second visit. Frequent exacerbator (future) indicated whether the subject had at least two self-reported exacerbations during the past 12 months before the third visit.

Top-10 Significant Gene Ontology enrichment terms for IEA_{emph}

GO terms	Description	Annotated	Significant	adjusted p-values
GO:0043312	neutrophil degranulation	461	239	2.60e-18
GO:0019083	viral transcription	174	99	4.20e-17
GO:0000184	nuclear-transcribed mRNA catabolic process, nonsense-mediated	119	79	2.00e-14
GO:0006614	SRP-dependent cotranslational protein targeting to membrane	99	65	2.20e-13
GO:0006413	translational initiation	185	93	2.30e-13
GO:0002181	cytoplasmic translation	98	51	2.20e-07
GO:0006364	rRNA processing	224	124	6.40e-07
GO:0006954	inflammatory response	529	250	4.40e-06
GO:0006955	immune response	1758	750	2.00e-05
GO:0045730	respiratory burst	33	20	3.30e-05

Top-10 Significant Gene Ontology enrichment terms for IEA_{airway}

GO terms	Description	Annotated	Significant	adjusted p-values
GO:0006396	RNA processing	981	204	1.80e-08
GO:0098869	cellular oxidant detoxification	77	33	1.00e-06
GO:0042744	hydrogen peroxide catabolic process	24	14	1.70e-05
GO:0006879	cellular iron ion homeostasis	56	25	7.30e-05
GO:0001895	retina homeostasis	43	16	9.10e-05
GO:0030449	regulation of complement activation	79	30	9.20e-05
GO:0019886	antigen processing and presentation of exogenous peptide antigen via MHC class II	90	32	1.00e-04
GO:0006413	translational initiation	185	53	1.00e-04
GO:0006614	SRP-dependent cotranslational protein targeting to membrane	99	34	2.40e-04
GO:0050900	leukocyte migration	377	89	5.20e-04

Table 5. Top-10 Significant Gene Ontology enrichment terms for IEAs. Gene ontology (GO) pathway enrichment analysis was performed using the GO "Biological Process" gene sets with p-values calculated with the Fisher exact test statistic using the weight01 algorithm in topGO *(23)* (v2.33.1) that accounts for dependency in GO topology.

Figure 1

Figure 2

Airway-Predominant

%Emphysema   =0
BMI   =31
%Wall Area   =64
FEV_1 %predicted =57
FEV_1/FVC   =0.76

Resistant Smoker

%Emphysema   =1
BMI   =19
%Wall Area   =46
FEV_1 %predicted =110
FEV_1/FVC   =0.79

**Emphysema-Predominant
with high BMI**

%Emphysema   =23
BMI   =31
%Wall Area   =49
FEV_1 %predicted =74
FEV_1/FVC   =0.48

**Emphysema-Predominant
with low BMI**

%Emphysema   =46
BMI   =22
%Wall Area   =46
FEV_1 %predicted =27
FEV_1/FVC   =0.37

FEV_1 % predicted

Figure 3

RRS: Relatively resistant smokers; UPE: Mild upper zone-predominant emphysema;
AP: Airway-predominant; SE: Severe emphysema.

Figure 4

Figure 5